Study details
Enrolling now
Luspatercept for Anemia
H. Lee Moffitt Cancer Center and Research Institute
NCT IDNCT05732961ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
70
Study length
about 3.6 years
Ages
18+
Locations
1 site in FL
What this study is about
Researchers are testing whether luspatercept, a medication, can help people with anemia related to Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasm (MPN) need fewer blood transfusions. The trial will also evaluate the safety and tolerability of luspatercept in these patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Luspatercept
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
luspatercept
Endpoints
Secondary: Duration of Response, Incidence of treatment related adverse events
Body systems
Oncology